State Street Corp Has $942,000 Stake in Personalis, Inc. (NASDAQ:PSNL)

State Street Corp increased its position in Personalis, Inc. (NASDAQ:PSNL) by 34.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 175,142 shares of the company’s stock after buying an additional 44,900 shares during the period. State Street Corp’s holdings in Personalis were worth $942,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its position in shares of Personalis by 11.4% in the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after purchasing an additional 723,637 shares during the period. Walleye Capital LLC bought a new position in Personalis in the 3rd quarter worth $897,000. Centiva Capital LP bought a new stake in Personalis during the third quarter valued at about $380,000. Semanteon Capital Management LP bought a new stake in Personalis during the third quarter valued at about $375,000. Finally, Acadian Asset Management LLC increased its stake in shares of Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after purchasing an additional 66,128 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Stock Up 8.5 %

Shares of PSNL opened at $6.27 on Friday. The stock’s 50-day moving average price is $4.60 and its 200 day moving average price is $4.17. The firm has a market capitalization of $442.96 million, a price-to-earnings ratio of -3.73 and a beta of 1.88. Personalis, Inc. has a 12-month low of $1.12 and a 12-month high of $7.20.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The firm had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. Equities research analysts expect that Personalis, Inc. will post -1.41 EPS for the current year.

Analysts Set New Price Targets

PSNL has been the subject of several recent analyst reports. HC Wainwright increased their target price on Personalis from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Friday, December 20th. Needham & Company LLC restated a “buy” rating and issued a $7.25 price objective on shares of Personalis in a research note on Friday, December 20th.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.